Health
ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools – News-Medical.net
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of ste…
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.
ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9. Companies can obtain licenses to this technology for in…
-
Noosa News22 hours agoUrgent warning to locals as multiple crews battle major industrial fire at Rocklea in Brisbane’s south
-
Noosa News24 hours agoSurfer attacked by Great White shark off northern NSW coast
-
Noosa News22 hours agoDr Vahid Reza Adib gives evidence at first day of inquest into the death of his patient Rosemarie Campbell
-
General24 hours agoCronulla Sharks captain Cameron McInnes to miss remainder of 2025 with second ACL rupture